摘要
目的:探讨尿激酶联合低分子肝素治疗不稳定性心绞痛(UAP)的临床疗效。方法:将63例UAP患者随机分为溶栓治疗组及常规治疗组,溶栓治疗组(33例)应用尿激酶联合低分子肝素治疗,观察心绞痛发作频率、发作间期、心电图ST段改变以及出凝血检测等,并与常规治疗组(30例)进行比较。结果:溶栓治疗组与常规治疗组的心绞痛发作频率、发作间期及心电图ST段均具有显著性差异,两组用药前、后KPTT、PLT及PT实验监测指标均无显著性差异。结论:尿激酶联合低分子肝素治疗不稳定型心绞痛简单、安全、临床疗效确切,值得在基层医院推广应用。
Objective: To discuss the clinic effects of urokinase combination with low molecular weight heparins treating unstable angina pectoris (UAP). Methods: Sixty-three patients with UAP were randomly divided thrombolysis therapeutic group (TTP) and routine therapeutic group (RTP). TTP (33 cases) was treated by Urokinase combination with low molecular weight heparins; UAP attack frequency, interval and ST segments alteration of electrocardiograph were observed. All results were compared with TTP (30 cases). Results: Two groups have significant differences in UAP attack frequency and interval and ST segments alteration; there have no significant differences in all experimental parameters of hemorrhage and blood coagulation. Conclusions: It is a simple, safety and precisely clinic effect that using Urokinase combination with low molecular weight heparins for treating UAP.
出处
《岭南急诊医学杂志》
2004年第1期7-8,15,共3页
Lingnan Journal of Emergency Medicine
